A phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. - Tolcher,A.W.; Kuhn,J.; Schwartz,G. (Clin Cancer Res, 2004)